Enanta Pharmaceuticals, Inc. (ENTA) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Watertown, MA, United States. The current CEO is Jay R. Luly.
ENTA has IPO date of 2013-03-21, 131 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $339.66M.
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
